(Reuters) – The European Medicines Agency (EMA) on Wednesday said its human medicines committee (CHMP) recommended authorizing an adapted Comirnaty COVID-19 vaccine targeting the dominant XBB.1.5 variant of Omicron.
The vaccine, developed by U.S. drugmaker Pfizer and German partner BioNTech, is to be used for preventing COVID-19 in adults and children from 6 months of age.
(Reporting by Eva Mathews in Bengaluru)
